Clinical Trial Update: Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of an adenovirus-vectored intranasal influenza vaccine targeting H5N1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza Infection

Drugs mentioned

• Adenovirus-vectored intranasal influenza vaccine (H5N1) (Adenovirus-vectored intranasal influenza vaccine)

Snippet

Sponsor: Altimmune, Inc. | Conditions: Influenza A Subtype H5N1 Infection | Phase 1 | Status: COMPLETED